MedImmune Inc., the Gaithersburg-based pharmaceutical known for its nasal influenza vaccine FluMist, has completed its acquisition of Cellective Therapeutics Inc.<@SM><@SM><TAB>MedImmune ...

AstraZeneca’s biologics division MedImmune is to spin out a new standalone biotech to develop six early-stage inflammation and autoimmunity programmes. To be known as Viela Bio, the spin-out ...

MedImmune was first to market with a swine flu vaccine in 2009. This year, it won approval for the first intranasal flu vaccine that contains four strains of the disease. Most vaccines contain three.

MedImmune Inc., the Washington region's most successful biotechnology company, is pinning its ambitions for growth on FluMist, an experimental vaccine whose development began some four decades ago.

After 16 years of guiding MedImmune Inc. from a struggling Gaithersburg biotech to one of the world’s most profitable, Chief Executive David M. Mott is stepping down for personal reasons, the ...

MedImmune Inc. on Monday agreed to buy vaccine maker Aviron in a bid to add FluMist, Aviron's promising treatment for influenza, to its own portfolio of drugs for infectious diseases.

MedImmune’s other approved drug is CytoGam, which generated $20.3 million in sales last year. It prevents a viral infection common after kidney transplantation.

MedImmune, a unit of AstraZeneca, said the changes will not disrupt delivery of the company’s vaccines. MedImmune is a major player in development of vaccines. Contact George Avalos at 925-977-8477.

Britain's AstraZeneca PLC last night was near the purchase of MedImmune Inc. for what could be more than $13 billion, people familiar with the negotiations said last night. Barring any last-minute ...

SAN FRANCISCO (MarketWatch) -- MedImmune Inc. late Monday said its first-quarter profit more than tripled over the same period last year, helped by lower costs and a 15% surge in revenue.

The Centers for Disease Control and Prevention's vaccine advisory committee is set to meet for the first time since Health ...